Sign in
Taking peoplePhase 3

Short course of low-dose heparin after childbirth to prevent blood clots

Tests low-dose heparin against no treatment for venous thromboembolism after delivery.

Key facts

Who runs it
Marc Blondon
Where
Switzerland9 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Status
Recruiting
Phase
Phase 3
People taking part
9,200 people, planned
Started
15 Oct 2025
Expected to end
Aug 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Low-dose low-molecular-weight heparin
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who have just given birth and have a higher chance of blood clots. It compares a short course of low-dose LMWH (a blood thinner) with no treatment.

Age
18 years and older
Sex
Women only
Disease stage
Just after giving birth, with at least 1 major or at least 2 minor risk factors for clots. Major: emergency cesarean section, pre-pregnancy BMI ≥35kg/m2, known low-risk thrombophilia, pre-eclampsia, pre-term delivery, infection around birth, baby's growth restriction in the womb, pregnancy loss. Minor: age ≥35 years, pre-pregnancy BMI 30.0-34.9kg/m2, current smoking, planned cesarean section, heavy bleeding after birth, being immobile before birth.
Earlier treatment
People who have already had 2 or more doses of LMWH after giving birth cannot join.
Biomarker or test result
Known low-risk thrombophilia counts as a major risk factor: heterozygous factor V Leiden or heterozygous G20210 prothrombin mutation.

Main reasons for not taking part

  • 2 or more doses of LMWH after giving birth
  • Any reason to need full-dose blood-thinning treatment
  • A high risk of blood clots after birth
  • A higher risk of bleeding
  • A reason you cannot take heparin

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg/m2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss
  • Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility

Who cannot take part

  • An increased bleeding risk
  • ≥2 doses of postpartum LMWH
  • Any indication for therapeutic anticoagulation
  • A high-risk of postpartum VTE
  • A contra-indication to heparin

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are:

Read full original descriptionShow less

* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

The 2 groups in the trial

  • Low-molecular-weight heparinTreatment being tested

    Treatment: Low-dose low-molecular-weight heparin

  • No treatmentNo study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study
Plain-language title
Short course of low-dose heparin after childbirth to prevent blood clotsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
6 October 2026